Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together

INDIANAPOLIS , April 12, 2021 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced changes to the purchase agreements with the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19.